Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study-Reference-Cited by-同舟云学术

Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study

Published:2016-09 Issue:9 Volume:17 Page:1295-1305
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Villani Anita,Shore Ari,Wasserman Jonathan D,Stephens Derek,Kim Raymond H,Druker Harriet,Gallinger Bailey,Naumer Anne,Kohlmann Wendy,Novokmet Ana,Tabori Uri,Tijerin Marta,Greer Mary-Louise C,Finlay Jonathan L,Schiffman Joshua D,Malkin David

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study;Villani;Lancet Oncol,2011

2. The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report;Jhaveri;Yale J Biol Med,2015

3. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers;Nichols;Cancer Epidemiol Biomarkers Prev,2001

4. ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data;Le Bihan;Genet Epidemiol,1995

5. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families;Jasperson;Fam Cancer,2014

Cited by 362 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol;Trials;2024-02-03

2. Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders;Best Practice & Research Clinical Haematology;2024-02

3. Li-Fraumeni syndrome presenting with de novo TP53 mutation, severe phenotype and advanced paternal age: a case report;Hereditary Cancer in Clinical Practice;2024-01-18

4. Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne;Cancer Medicine;2024-01-17

5. Is It Time to Incorporate Liquid Biopsy into High-Risk Cancer Surveillance Protocols in Li–Fraumeni Syndrome?;Cancer Discovery;2024-01-12